Regression of experimental endometriotic implants in a rat model with the angiotensin II receptor blocker losartan

Bülent Çakmak, Bulent Cakmak, Cavusoglu T, Turker Cavusoglu, Türker Çavuşoğlu, Utku Ates, Utku Ateş, Ayfer Meral, Nacar MC, Mehmet Can Nacar, Oytun Erbaş
Journal of Obstetrics and Gynaecology Research · 2014 · vol. 41(4) , pp. 601–607 · doi:10.1111/jog.12558 · PMID:25302540 · W1947362627
article OA: closed CC0 ⤵ 5 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

Losartan treatment in a rat model reduced endometriotic implant size and decreased plasma levels of VEGF, TNF-α, PTX-3, and CRP.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

AIM: Endometriosis is a common disease in women of reproductive age, and many different treatments have been developed, although none has provided a cure. In this study, the efficacy of losartan, an angiotensin II type 1 receptor blocker and an antiangiogenic and anti-inflammatory agent, on regression of experimental endometriotic implants in a rat model was investigated. METHODS: Peritoneal endometriosis was surgically induced in 16 mature female Sprague-Dawley rats. The peritoneal endometriotic implant was confirmed after 28 days, and the animals were divided randomly into two groups. The control group (n = 8) was given 4 mL/day tap water by oral gavage, and the losartan group (n = 8) was given 20 mg/kg per day losartan p.o. We compared endometriotic implant size, extent and severity of adhesion, as well as plasma and peritoneal lavage fluid cytokine levels including vascular endothelial growth factor (VEGF) and tumor necrosis factor (TNF)-α, plasma inflammatory factor pentraxin-3 (PTX-3) and C-reactive protein (CRP) between the treatment groups. RESULTS: Mean surface endometriotic area, histological score of implants, adhesion formation, plasma VEGF, TNF, PTX-3 and CRP levels were significantly lower in the losartan group compared with control (P < 0.05). Furthermore, the peritoneal VEGF level was lower in the losartan group than in the control group (P 0.05). CONCLUSION: Losartan suppressed the implant surface area of experimental endometriosis in rats and reduced the levels of plasma VEGF, TNF-α, PTX-3 and CRP.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Angiotensin Receptor Antagonists Endometriosis Losartan Peritoneal Diseases Angiotensin Receptor Antagonists Animals C-Reactive Protein C-Reactive Protein Cytokines Cytokines Disease Models, Animal Endometriosis Endometriosis Female Losartan Pentraxins Peritoneal Diseases Peritoneal Diseases Rats Rats, Sprague-Dawley

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (42)

Cited by (5)

Source provenance

europepmc
last seen: 2026-08-25T06:10:03.373225+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:18:15.805398+00:00
License: CC0 · commercial use OK